Persistent Identifier
|
doi:10.7910/DVN/SOBL4B |
Publication Date
|
2023-04-20 |
Title
| Data for: Mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens in preparation for BOHEMIA cluster randomized controlled trial |
Author
| Maia, Marta F.KEMRI-Wellcome Trust Research Programme, Kilifi, KenyaORCIDhttps://orcid.org/0000-0003-3302-5610
Kamau, YvonneKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Tuwei, MercyKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Ominde, KellyKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Ngama, MwanajumaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Karisa, JonathanKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Babu, LawrenceKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Muturi, MarthaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Lewa,FridaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Mure, FestusKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Mwatasa, MwaganyumaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Wanjiku, CarolineKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Adetifa, JaneKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Kern, CharlotteDivision of Clinical Pharmacology & Toxicology, Department of Internal Medicine, University Hospital Bern, Switzerland
Duthaler, UrsDivision of Clinical Pharmacology & Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel,Switzerland
Hammann,FelixDivision of Clinical Pharmacology & Toxicology, Department of Internal Medicine, University Hospital Bern, Switzerland
Rabinovich,ReginaISGlobal, Barcelona Institute for Global Health, Barcelona, Spain
Chaccour, CarlosISGlobal, Barcelona Institute for Global Health, Barcelona, Spain |
Point of Contact
|
Use email button above to contact.
Mwango, Lillian (KEMRI-Wellcome Trust Research programme) |
Description
| The aim of the trial was to compare the pharmacokinetics and mosquito-killing effect of 300 mcg/kg of IVM given on three consecutive days to 400 mcg/kg of IVM given once. The trial also evaluated how the two treatments differed from albendazole in terms of mosquito survival
Mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens given to both male and female healthy participants who were willing to comply with study requirements. The study participants were residents of Ngerenya, Kilifi, Kenya
The datasets describe the process of screening the participants and randomization into the study arms for eligible individuals. Participants screened 30 days to study allocation were screened again to check on their eligibility. Participants were treated and followed up according to the group to which the participant was assigned. Participants who were dropped off from the study were registered in the withdrawal form.
The trial is registered on clinicaltrials.gov: NCT04966702 |
Subject
| Medicine, Health and Life Sciences |
Keyword
| Anopheles gambiae
malaria
ivermectin
mass drug administration |
Related Publication
| Manuscripts in preparation |
Notes
| Data Access: Restricted
Access to these data requires submission of a formal request for consideration by our Data Governance Committee. How to request
- Download and complete the data request form
- Email completed data request form to the Data Governance Committee at dgc@kemri-wellcome.org
|
Depositor
| Maia, Marta F. |
Deposit Date
| 2023-04-12 |
Data Type
| Clinical Trial; Restricted |